NO975546L - Antigene gruppe B-streptokokk-type II- og type III-polysakkaridfragmenter med en 2,5-anhydro-D-mannose-terminal struktur samt en konjugatvaksine derav - Google Patents

Antigene gruppe B-streptokokk-type II- og type III-polysakkaridfragmenter med en 2,5-anhydro-D-mannose-terminal struktur samt en konjugatvaksine derav

Info

Publication number
NO975546L
NO975546L NO975546A NO975546A NO975546L NO 975546 L NO975546 L NO 975546L NO 975546 A NO975546 A NO 975546A NO 975546 A NO975546 A NO 975546A NO 975546 L NO975546 L NO 975546L
Authority
NO
Norway
Prior art keywords
type
anhydro
well
terminal structure
conjugate vaccine
Prior art date
Application number
NO975546A
Other languages
English (en)
Norwegian (no)
Other versions
NO975546D0 (no
Inventor
Francis Michon
Chatherine Uitz
Y Tai Joseph
Original Assignee
North American Vaccine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North American Vaccine Inc filed Critical North American Vaccine Inc
Publication of NO975546D0 publication Critical patent/NO975546D0/no
Publication of NO975546L publication Critical patent/NO975546L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Surgical Instruments (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO975546A 1995-06-07 1997-12-02 Antigene gruppe B-streptokokk-type II- og type III-polysakkaridfragmenter med en 2,5-anhydro-D-mannose-terminal struktur samt en konjugatvaksine derav NO975546L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/481,883 US6284884B1 (en) 1995-06-07 1995-06-07 Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
PCT/US1996/009294 WO1996040795A1 (fr) 1995-06-07 1996-06-06 Fragments antigeniques de polysaccharides de streptocoques de types ii et iii du groupe b, presentant une structure terminale 2,5-anhydro-d-mannose et vaccins conjugues a base desdits fragments

Publications (2)

Publication Number Publication Date
NO975546D0 NO975546D0 (no) 1997-12-02
NO975546L true NO975546L (no) 1998-02-06

Family

ID=23913768

Family Applications (1)

Application Number Title Priority Date Filing Date
NO975546A NO975546L (no) 1995-06-07 1997-12-02 Antigene gruppe B-streptokokk-type II- og type III-polysakkaridfragmenter med en 2,5-anhydro-D-mannose-terminal struktur samt en konjugatvaksine derav

Country Status (15)

Country Link
US (3) US6284884B1 (fr)
EP (1) EP0830380B1 (fr)
JP (1) JP4001625B2 (fr)
KR (1) KR100431236B1 (fr)
AT (1) ATE236194T1 (fr)
AU (1) AU706479B2 (fr)
CA (1) CA2223080C (fr)
DE (1) DE69627149T2 (fr)
ES (1) ES2200067T3 (fr)
HU (1) HUP9900919A3 (fr)
IL (3) IL136125A (fr)
NO (1) NO975546L (fr)
PL (1) PL187822B1 (fr)
WO (1) WO1996040795A1 (fr)
ZA (1) ZA964822B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2420247A1 (fr) * 2000-08-22 2002-02-28 National Research Council Of Canada Synthese de glucides complexes
CA2881568C (fr) 2000-10-27 2019-09-24 Novartis Vaccines And Diagnostics, Inc. Acides nucleiques et proteines derives des groupes de streptocoques a et b
WO2004011027A1 (fr) * 2002-07-30 2004-02-05 Baxter International Inc. Vaccins multivalents chimeres a conjugue polysaccharidique
US20070053924A1 (en) * 2002-08-26 2007-03-08 Herve Tettelin Conserved and specific streptococcal genomes
ES2504166T3 (es) * 2002-09-13 2014-10-08 Novartis Vaccines And Diagnostics, Inc. Vacuna de estreptococo del grupo B
EP1638601B1 (fr) * 2003-06-23 2008-11-19 Baxter International Inc. Proteines porteuses pour des vaccins
ES2505695T3 (es) 2003-07-31 2014-10-10 Novartis Vaccines And Diagnostics, Inc. Composiciones inmunógenas para Streptococcus pyogenes
US8945589B2 (en) * 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
JP2008508320A (ja) 2004-07-29 2008-03-21 カイロン コーポレイション Ｓｔｒｅｐｔｏｃｏｃｃｕｓａｇａｌａｃｔｉａｅのようなグラム陽性細菌に対する免疫原性組成物
US7838010B2 (en) * 2004-10-08 2010-11-23 Novartis Vaccines And Diagnostics S.R.L. Immunogenic and therapeutic compositions for Streptococcus pyogenes
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
CA2620416A1 (fr) * 2005-08-24 2007-03-01 Novartis Vaccines And Diagnostics S.R.L. Zwitterionisation de saccharides capsulaires
PT2054431E (pt) * 2006-06-09 2011-11-03 Novartis Ag Confórmeros de adesinas bacterianas
CA2668018A1 (fr) * 2006-10-30 2008-09-12 Novartis Ag Compositions immunogenes et therapeutiques pour streptococcus pyogenes
ES2528648T3 (es) * 2007-09-11 2015-02-11 University Of Guelph Inmunógenos polisacáridos de la Clostridium Difficile
KR101621837B1 (ko) 2007-09-12 2016-05-17 노파르티스 아게 Ｇａｓ57 돌연변이 항원 및 ｇａｓ57 항체
EP2537857B1 (fr) 2007-12-21 2017-01-18 GlaxoSmithKline Biologicals SA Formes mutantes de streptolysine O
JP5841044B2 (ja) * 2009-03-23 2016-01-06 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 複合糖質ワクチン
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
EP2729178A1 (fr) 2011-07-08 2014-05-14 Novartis AG Procédé de ligature de la tyrosine
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
RU2636350C2 (ru) 2011-11-07 2017-11-22 Новартис Аг МОЛЕКУЛА, СОДЕРЖАЩАЯ SPR0096 и SPR2021
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
RU2015106791A (ru) 2012-10-03 2016-11-20 Глэксосмитиклайн Байолоджикалз Са Иммуногенные композиции
WO2014158963A1 (fr) * 2013-03-12 2014-10-02 Wellstat Vaccines, Llc Anticorps ciblés sur des polysaccharides de parois cellulaires fongiques
AU2014286990A1 (en) 2013-07-11 2016-02-11 Novartis Ag Lysine-specific chemoenzymatic protein modifications using microbial transglutaminase
BE1024634B1 (fr) 2016-04-05 2018-05-14 Gsk Vaccines S.R.L. Compositions immunogenes
MX2022015860A (es) 2020-06-12 2023-01-24 Glaxosmithkline Biologicals Sa Inmunizacion bacteriana que utiliza una vacuna con nanoparticulas.
WO2023111826A1 (fr) 2021-12-14 2023-06-22 Glaxosmithkline Biologicals Sa Immunisation bactérienne utilisant des constructions de nanoparticules en épingle à cheveux qbêta
WO2025172892A1 (fr) 2024-02-16 2025-08-21 Glaxosmithkline Biologicals Sa Protéines modifiées et méthodes

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3352773A (en) 1964-09-16 1967-11-14 Gillette Res Inst Inc Method of degrading polysaccharides using light radiation and a watersoluble metal or nitrogen base salt of nitrous or hyponitric acid
US3922260A (en) 1973-08-24 1975-11-25 Quintin P Peniston Process for depolymerization of chitosan
US4207414A (en) 1978-08-16 1980-06-10 President And Fellows Of Harvard College Polysaccharide antigens
US4324887A (en) * 1978-08-16 1982-04-13 President And Fellows Of Harvard College Type II group B Streptococci polysaccharide
US4500519A (en) * 1978-11-06 1985-02-19 Choay S.A. Mucopolysaccharides having biological properties, preparation and method of use
US4439422A (en) 1980-01-02 1984-03-27 Research Corporation Group B Streptococcus antigens and vaccines
US4413057A (en) 1980-04-14 1983-11-01 Merck & Co., Inc. Group B streptococcal capsular polysaccharides
IE51174B1 (en) 1980-04-14 1986-10-29 Merck & Co Inc Group b streptococcal capsular polysaccharides
US4438261A (en) 1980-05-19 1984-03-20 Riker Laboratories, Inc. Anticoagulant substance
US4367221A (en) 1980-06-09 1983-01-04 President And Fellows Of Harvard College Immunization against Group B streptococci
US4356263A (en) 1980-06-09 1982-10-26 President And Fellows Of Harvard College Method of making a polysaccharide vaccine
US4367222A (en) 1980-06-09 1983-01-04 President And Fellows Of Harvard College Immune globulin specific to Group B streptococci
US4367223A (en) 1980-06-09 1983-01-04 President And Fellows Of Harvard College Vaccine against Group B streptococci
US4284537A (en) 1980-07-03 1981-08-18 The United States Of America As Represented By The Department Of Health And Human Services Conjugate of streptococcal M protein peptide vaccine
US4425330A (en) 1981-05-20 1984-01-10 Cornell Research Foundation, Inc. Bovine mastitis vaccine and method for detecting efficacy thereof
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4619828A (en) 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4757134A (en) 1982-12-02 1988-07-12 The Rockefeller University IgA binding protein
ATE70308T1 (de) 1984-09-12 1991-12-15 Chiron Corp Hybridpartikel-immunogene.
FR2581877B1 (fr) 1985-05-14 1987-12-18 Louvain Universite Catholique Conjugue constitue d'une adhesine de paroi de s. mutans, de nature proteique et d'un polysaccharide de s. mutans, sa preparation et son utilisation notamment dans des vaccins anti-caries
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US5302386A (en) 1986-04-16 1994-04-12 Brigham And Women's Hospital, Inc. Bacterial antigens, antibodies, vaccines and methods of manufacture
JP2754000B2 (ja) 1986-04-16 1998-05-20 ザ ブリガム アンド ウィメンズ ホスピタル，インコーポレイテッド 細菌抗原、抗体、ワクチン及びその製造方法
NZ225372A (en) 1987-07-17 1991-04-26 Xoma Corp Immunotoxin composition comprising purified ricin-a-chain species
JP2871822B2 (ja) 1989-08-29 1999-03-17 玉造株式会社 末端に２，５―アンヒドロマンニトール基または２，５―アンヒドロマンノース基を有するキチン・キトサンオリゴマーおよびその製造方法
IL95578A (en) 1989-09-15 1998-08-16 Gen Hospital Corp Conjugate vaccine formed from a polysaccharide and a c protein of b-streptococcus
JPH05502157A (ja) 1989-09-18 1993-04-22 ブリガム アンド ウィメンズ ホスピタル グループｂ連鎖球菌３型莢膜オリゴ糖の酵素学的産生及び回収
HU9201966D0 (en) 1989-12-14 1992-10-28 Ca Nat Research Council An improved vaccine of meningococcus-polysaccharide conjunction
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
JPH06506114A (ja) 1991-03-29 1994-07-14 ファウルマン，　エルビン 新規な遺伝子及びＩｇＡ結合蛋白質の製造方法
FR2682388B1 (fr) 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
US5352588A (en) 1991-12-24 1994-10-04 Rockefeller University Streptococcal immunoglobulin a binding protein encoded by emmL2.2
WO1993015217A1 (fr) * 1992-02-04 1993-08-05 Quidel Corporation Procede d'extraction simplifie d'antigenes bacteriens au moyen de reactifs deshydrates
ZA937034B (en) 1992-09-24 1995-06-23 Brigham & Womens Hospital Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines
IL107458A0 (en) 1992-11-02 1994-02-27 Gen Hospital Corp Conjugate vaccine against group b streptococcus
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5595740A (en) * 1994-05-16 1997-01-21 University Of Florida Cloning of non-IgA FC binding forms of the group B streptococcal beta antigens
WO2000038265A1 (fr) 1998-12-22 2000-06-29 Mitsubishi Denki Kabushiki Kaisha Solution electrolytique pour cellules et cellules fabriquees avec une telle solution

Also Published As

Publication number Publication date
DE69627149T2 (de) 2003-12-04
IL118603A (en) 2000-12-06
KR19990022747A (ko) 1999-03-25
US6284884B1 (en) 2001-09-04
US6602508B2 (en) 2003-08-05
EP0830380A1 (fr) 1998-03-25
WO1996040795A1 (fr) 1996-12-19
CA2223080C (fr) 2007-03-20
ZA964822B (en) 1997-01-07
PL187822B1 (pl) 2004-10-29
EP0830380B1 (fr) 2003-04-02
ES2200067T3 (es) 2004-03-01
HUP9900919A2 (hu) 1999-06-28
DE69627149D1 (de) 2003-05-08
IL136125A0 (en) 2001-05-20
CA2223080A1 (fr) 1996-12-19
IL136125A (en) 2006-08-01
IL118603A0 (en) 1996-10-16
JP4001625B2 (ja) 2007-10-31
US6372222B1 (en) 2002-04-16
AU6095396A (en) 1996-12-30
NO975546D0 (no) 1997-12-02
HUP9900919A3 (en) 2000-04-28
ATE236194T1 (de) 2003-04-15
AU706479B2 (en) 1999-06-17
JPH11507964A (ja) 1999-07-13
PL323822A1 (en) 1998-04-27
US20020031526A1 (en) 2002-03-14
KR100431236B1 (ko) 2004-09-16

Similar Documents

Publication Publication Date Title
NO975546L (no) Antigene gruppe B-streptokokk-type II- og type III-polysakkaridfragmenter med en 2,5-anhydro-D-mannose-terminal struktur samt en konjugatvaksine derav
IL115047A0 (en) Pneumococcal polysaccharide - recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections.
Anderson Antibody responses to Haemophilus influenzae type b and diphtheria toxin induced by conjugates of oligosaccharides of the type b capsule with the nontoxic protein CRM197
Mawas et al. Immunogenicity in a mouse model of a conjugate vaccine made with a synthetic single repeating unit of type 14 pneumococcal polysaccharide coupled to CRM197
NO20004161L (no) Gruppe B streptokoccus antigener
JP2002539272A5 (fr)
DE69941574D1 (de) Immunogenes beta-propionamido-gebundenes polysaccharid-protein konjugat geeignet als impfstoff und hergestellt bei verwendung von n-acryloyliertem polysaccharid
ATE112687T1 (de) Mutanten des hiv-1 hüllproteins mit fehlenden hypervariabelen domänen.
NO964413L (no) Gruppe A streptokokkisk polysakkarid, immunogene blandinger derav samt anvendelse derav
BR9811475A (pt) Conjugados imunogênicos compreendendo uma porina meningocóccica de grupo b e um polissacarìdeo de h. influenzae
ATE212233T1 (de) Impfstoffe gegen neisseria meningitidis gruppe c
NO975547D0 (no) Vaksiner med modifiserte meningokokk/polysakkarid-konjugater
US4771127A (en) Nontoxic pseudomonas aeruginosa polysaccharide-tetanus toxoid and polysaccharide-toxin a conjugate vaccines
CO5300414A1 (es) Composiciones de vacunas con antigenos de streptococus de virus vsr y adyuvante estimulador de respuesta th1
ID21338A (id) Metoda untuk menghasilkan kekebalan aktif dengan vaksin gabungan
CA2145397A1 (fr) Vaccins conjugues polysaccharides-proteines contre des streptocoques du groupe b de types ii et v
DK0491865T3 (da) Konjugatvaccine for gruppe B-Streptococcus
DE69130955D1 (de) Adhesin-oligosaccharid-impfstoffkonjugate für -i(haemophilus influenza)
US6165468A (en) Antigenic carbohydrate linked to an immunogenic carrier
WO2002013861A3 (fr) Methode et composition de modification d'une pathologie a mediation assuree par les lymphocytes t
Schneerson et al. Bacterial capsular polysaccharide conjugates.
RU2001107132A (ru) Иммуногенный конъюгат бета-пропионамид-связанного полисахарида с белком, использующийся в качестве вакцины, который получают с помощью n-акрилоилированного полисахарида
Cryz Jr et al. Toxoids of Pseudomonas aeruginosa toxin A: production by chemical and genetic means
DE60031106D1 (de) Fluordesoxyuridin-resistente streptococcus gordonii stämme